MPH Fundamental Analysis - MEDICURE INC

Fundamental Rating

MPH gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 23 industry peers in the Biotechnology industry. MPH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MPH does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

MPH had negative earnings in the past year.

In the past year MPH had a positive cash flow from operations.

MPH had negative earnings in 4 of the past 5 years.

Of the past 5 years MPH 4 years had a positive operating cash flow.

1.2 Ratios

MPH has a Return On Assets of -4.76%. This is amongst the best in the industry. MPH outperforms 91.30% of its industry peers.

With an excellent Return On Equity value of -7.39%, MPH belongs to the best of the industry, outperforming 86.96% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-4.76%
ROE	-7.39%
ROIC	N/A

ROA(3y)-0.74%

ROA(5y)-4.98%

ROE(3y)-1.05%

ROE(5y)-8.57%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 53.95%, MPH belongs to the best of the industry, outperforming 82.61% of the companies in the same industry.

In the last couple of years the Gross Margin of MPH has remained more or less at the same level.

The Profit Margin and Operating Margin are not available for MPH so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	53.95%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.73%

GM growth 5Y-1.35%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MPH does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, MPH has about the same amount of shares outstanding.

MPH has less shares outstanding than it did 5 years ago.

MPH has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -1.87, we must say that MPH is in the distress zone and has some risk of bankruptcy.

MPH's Altman-Z score of -1.87 is fine compared to the rest of the industry. MPH outperforms 65.22% of its industry peers.

MPH has a debt to FCF ratio of 1.19. This is a very positive value and a sign of high solvency as it would only need 1.19 years to pay back of all of its debts.

MPH has a better Debt to FCF ratio (1.19) than 95.65% of its industry peers.

A Debt/Equity ratio of 0.03 indicates that MPH is not too dependend on debt financing.

MPH has a Debt to Equity ratio of 0.03. This is in the better half of the industry: MPH outperforms 69.57% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF	1.19
Altman-Z	-1.87

ROIC/WACCN/A

WACC7.57%

2.3 Liquidity

MPH has a Current Ratio of 1.48. This is a normal value and indicates that MPH is financially healthy and should not expect problems in meeting its short term obligations.

Looking at the Current ratio, with a value of 1.48, MPH is in line with its industry, outperforming 56.52% of the companies in the same industry.

MPH has a Quick Ratio of 1.06. This is a normal value and indicates that MPH is financially healthy and should not expect problems in meeting its short term obligations.

Looking at the Quick ratio, with a value of 1.06, MPH is in line with its industry, outperforming 56.52% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.48
Quick Ratio	1.06

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for MPH have decreased strongly by -700.00% in the last year.

The Revenue for MPH has decreased by -30.70% in the past year. This is quite bad

The Revenue has been growing by 30.82% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-700%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-279.68%

Revenue 1Y (TTM)-30.7%

Revenue growth 3Y-11.7%

Revenue growth 5Y30.82%

Sales Q2Q%56.6%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MPH. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

95.65% of the companies in the same industry are more expensive than MPH, based on the Price/Free Cash Flow ratio.

		Industry Rank	Sector Rank
P/FCF	15.35
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

MPH does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MEDICURE INC

TSX-V:MPH (11/28/2025, 7:00:00 PM)

1.35

+0.25 (+22.73%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-19 2025-11-19/amc

Earnings (Next)04-27 2026-04-27

Inst Owners23.1%

Inst Owner ChangeN/A

Ins Owners26.42%

Ins Owner ChangeN/A

Market Cap14.09M

Revenue(TTM)20.17M

Net Income(TTM)-1.35M

Analysts40

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.61
P/FCF	15.35
P/OCF	9.61
P/B	0.77
P/tB	2.67
EV/EBITDA	N/A

EPS(TTM)-1.32

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0.09

FCFY6.51%

OCF(TTM)0.14

OCFY10.4%

SpS2.22

BVpS1.75

TBVpS0.51

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-4.76%
ROE	-7.39%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	53.95%
FCFM	3.96%

ROA(3y)-0.74%

ROA(5y)-4.98%

ROE(3y)-1.05%

ROE(5y)-8.57%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.73%

GM growth 5Y-1.35%

F-Score4

Asset Turnover0.82

Health

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF	1.19
Debt/EBITDA	N/A
Cap/Depr	21.95%
Cap/Sales	2.36%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.48
Quick Ratio	1.06
Altman-Z	-1.87

F-Score4

WACC7.57%

ROIC/WACCN/A

Cap/Depr(3y)19.82%

Cap/Depr(5y)17.11%

Cap/Sales(3y)1.99%

Cap/Sales(5y)1.95%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-700%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-279.68%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-30.7%

Revenue growth 3Y-11.7%

Revenue growth 5Y30.82%

Sales Q2Q%56.6%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-16.43%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-5.07%

FCF growth 3Y-41.4%

FCF growth 5YN/A

OCF growth 1Y28.15%

OCF growth 3Y-29.85%

OCF growth 5YN/A

MEDICURE INC / MPH.CA FAQ

Can you provide the ChartMill fundamental rating for MEDICURE INC?

ChartMill assigns a fundamental rating of 3 / 10 to MPH.CA.

Can you provide the valuation status for MEDICURE INC?

ChartMill assigns a valuation rating of 2 / 10 to MEDICURE INC (MPH.CA). This can be considered as Overvalued.

What is the profitability of MPH stock?

MEDICURE INC (MPH.CA) has a profitability rating of 3 / 10.

MEDICURE INC (MPH.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

MEDICURE INC / MPH.CA FAQ

Can you provide the ChartMill fundamental rating for MEDICURE INC?

Can you provide the valuation status for MEDICURE INC?

What is the profitability of MPH stock?